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OBJECTIVES: Diagnosis of pancreatic cancer is challenging as patients may be relatively 
asymptomatic during its early course. PET/CT may improve diagnosis and staging of pancreatic 
cancer but is not widely used across the UK. There is uncertainty whether PET/CT represents good 
value for money. This study aimed to model the cost-effectiveness of PET/CT compared with 
multidetector computed tomography (MDCT) alone in the diagnosis and management of patients 
with pancreatic cancer, based on data collected from the multi-centre PET-PANC cohort study.  
METHODS: A decision-analytic model was developed to compare patient pathways following 
diagnosis with PET/CT compared with MDCT alone. Patient management strategies following PET/CT 
were taken from PET-PANC. Patient management strategies following MDCT alone were based on 
clinical interpretation of the initial MDCT diagnosis. Event-based regressions were used associate 
strategies with cost and QALY data collected during PET-PANC. Analysis was conducted from the 
perspective of the UK National Health Service (NHS), over a 12-month time-horizon. Uncertainty was 
considered in univariate and multivariate sensitivity analyses. Subgroup analysis considered the 
impact of PET/CT on patients with diagnosis of chronic pancreatitis; malignancy; and those who 
were scheduled for resection surgery.  
RESULTS: The mean total cost and QALYs of pancreatic cancer service use over 12-months were 
£13,193 per patient (95% confidence interval (CI): £11,634, £14,802), and 0.5540 (95% CI: 0.5261, 
0.5811), respectively. PET/CT dominated MDCT, being both less costly and more effective. The 
largest cost saving and highest QALY gain were seen for the subgroup scheduled for resection 
surgery. The probability of cost-effectiveness at a threshold of £20,000/QALY was 82%.  
CONCLUSIONS: It is likely that use of PET/CT in the diagnosis and staging of pancreatic cancer is cost-
effective for the UK NHS, with the most cost-effective use of PET/CT being in patients who are 
suspected of having pancreatic cancer and are scheduled for resection surgery following MDCT. 
 
